Physician profile
Debora D Shpolyansky
NPI 1750310058
$3,208.15
in general payments reported to CMS, 2019-2025
30 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,774 · 2020: $326 · 2021: $272 · 2022: $236 · 2023: $230 · 2024: $204 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $782.34 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $418.23 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $330.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $201.98 | 2019-2025 | |
| Amgen INC. | $150.89 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $130.08 | 2019-2020 | |
| Lilly USA, LLC | $129.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $87.31 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $80.35 | 2023-2024 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $59.02 | 2019-2020 | |
| Allergan, INC. | $52.40 | 2019 | |
| Abbott Laboratories | $51.31 | 2025 | Freestyle Libre |
| Exact Sciences Corporation | $50.27 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $45.44 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $40.02 | 2020 | |
| Pfizer INC. | $39.99 | 2025 | |
| Zyla Life Sciences, INC. | $38.72 | 2019 | |
| Eisai INC. | $34.61 | 2019 | |
| Phadia US INC. | $31.18 | 2021 | |
| Astellas Pharma US INC | $23.07 | 2019 | |
| Edwards Lifesciences Corporation | $19.32 | 2020 | |
| Genentech USA, INC. | $18.40 | 2019 | |
| Esperion Therapeutics, INC. | $17.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.71 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.50 | 2024 | |
| Nalpropion Pharmaceuticals LLC | $16.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.63 | 2019 | |
| Abbvie INC. | $12.79 | 2019 | |
| Horizon Therapeutics Plc | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debora Shpolyansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.